Holen Sie sich die Stockscreener-App
3.56
3.26%
-0.12
Handel nachbörslich:
3.57
0.010
+0.28%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$3.68
Offen:
$3.65
24-Stunden-Volumen:
1.73M
Relative Volume:
0.31
Marktkapitalisierung:
$314.20M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.1707
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
-4.04%
1M Leistung:
-0.56%
6M Leistung:
-40.27%
1J Leistung:
-45.23%
1-Tages-Spanne:
$3.535
$3.65
1-Wochen-Bereich:
$3.535
$3.855
52-Wochen-Spanne:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.56 | 330.96M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - PR Newswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming DeadlinesALT - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, - GlobeNewswire
Investors in Altimmune, Inc. (ALT): Protect Your RightsContact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
Securities Lawsuit Alert: Altimmune, Inc. (ALT)Contact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
Will breakout in Altimmune Inc. lead to full recoveryJuly 2025 Trends & Safe Investment Capital Preservation Plans - Newser
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm - WV News
What MACD signals say about Altimmune Inc.Quarterly Portfolio Review & Risk Managed Investment Strategies - Newser
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. - GlobeNewswire
Altimmune, Inc. (ALT) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
Will Altimmune Inc. price bounce be sustainableWeekly Gains Summary & Weekly Breakout Stock Alerts - Newser
SHAREHOLDER ALERT: Berger Montague Reminds Altimmune, Inc. (NASDAQ: ALT) Investors of Class Action Lawsuit Deadline - Eastern Progress
Using data models to predict Altimmune Inc. stock movementJuly 2025 Trade Ideas & Verified Entry Point Detection - Newser
Will Altimmune Inc. outperform the marketEarnings Growth Summary & Stepwise Swing Trade Plans - Newser
Is Altimmune Inc. stock bottoming out2025 Year in Review & Risk Controlled Swing Trade Alerts - Newser
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your RightsALT - WV News
Strategies to average down on Altimmune Inc.2025 Sector Review & Stock Portfolio Risk Control - Newser
Class Action Filed Against Altimmune, Inc. (ALT) Over Securities ViolationsContact Levi & Korsinsky Today - Newsfile
Activist Investor Opportunities and Corporate Governance Risks in Altimmune’s Securities Fraud Litigation - AInvest
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - PR Newswire
Wellington Management Group LLP Grows Stock Holdings in Altimmune, Inc. $ALT - Defense World
Altimmune Inc. stock prediction for this weekWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
Securities Fraud Class Action Filed Against Altimmune, Inc. (ALT)Levi & Korsinsky Reminds Investors of October 6, 2025 - ACCESS Newswire
Developing predictive dashboards with Altimmune Inc. dataTake Profit & Expert Curated Trade Setup Alerts - Newser
Identifying reversal signals in Altimmune Inc.2025 Stock Rankings & High Yield Equity Trading Tips - Newser
Will Altimmune Inc. see short term momentumJuly 2025 EndofMonth & Long-Term Safe Investment Ideas - Newser
Can you recover from losses in Altimmune Inc.July 2025 Pullbacks & Expert Verified Movement Alerts - Newser
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Altimmune, Inc. (ALT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of October 6, 2025 Deadline - ACCESS Newswire
Deutsche Bank AG Raises Position in Altimmune, Inc. $ALT - Defense World
Altimmune, Inc. $ALT Position Cut by Vanguard Group Inc. - Defense World
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class ActionALT - Eastern Progress
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - The National Law Review
Levi & Korsinsky Notifies Altimmune, Inc. (ALT) Shareholders of Class Action Lawsuit and October 6, 2025 Deadline - ACCESS Newswire
Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade) (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Sued for Securities Law Violations – - GlobeNewswire
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Altimmune Inc-Aktie (ALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):